OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

查看量	下载量

相关文章
更多...

PLOS ONE 2012

Isolation and Characterisation of a Human-Like Antibody Fragment (scFv) That Inactivates VEEV In Vitro and In Vivo

DOI: 10.1371/journal.pone.0037242

Torsten Rülker, Luzie Vo？, Philippe Thullier, Lyn M. O' Brien, Thibaut Pelat, Stuart D. Perkins, Claudia Langermann, Thomas Schirrmann, Stefan Dübel, Hans-Jürgen Marschall, Michael Hust, Birgit Hülseweh

Full-Text Cite this paper Add to My Lib

Abstract:

Venezuelan equine encephalitis virus (VEEV) belongs to the Alphavirus genus and several species of this family are pathogenic to humans. The viruses are classified as potential agents of biological warfare and terrorism and sensitive detection as well as effective prophylaxis and antiviral therapies are required. In this work, we describe the isolation of the anti-VEEV single chain Fragment variable (scFv), ToR67-3B4, from a non-human primate (NHP) antibody gene library. We report its recloning into the bivalent scFv-Fc format and further immunological and biochemical characterisation. The scFv-Fc ToR67-3B4 recognised viable as well as formalin and ？-propionolactone (？-Pl) inactivated virus particles and could be applied for immunoblot analysis of VEEV proteins and immuno-histochemistry of VEEV infected cells. It detected specifically the viral E1 envelope protein of VEEV but did not react with reduced viral glycoprotein preparations suggesting that recognition depends upon conformational epitopes. The recombinant antibody was able to detect multiple VEEV subtypes and displayed only marginal cross-reactivity to other Alphavirus species except for EEEV. In addition, the scFv-Fc fusion described here might be of therapeutic use since it successfully inactivated VEEV in a murine disease model. When the recombinant antibody was administered 6 hours post challenge, 80% to 100% of mice survived lethal VEEV IA/B or IE infection. Forty to sixty percent of mice survived when scFv-Fc ToR67-3B4 was applied 6 hours post challenge with VEEV subtypes II and former IIIA. In combination with E2-neutralising antibodies the NHP antibody isolated here could significantly improve passive protection as well as generic therapy of VEE.

References

[1]	Kubes V, Ríos FA (1939) The causative agent of infectious Equine Encephalomyelitis in Venezuela. Science 90: 20–21.
[2]	Powers AM, Brault AC, Shirako Y, Strauss EG, Kang W, et al. (2001) Evolutionary Relationships and Systematics of the Alphaviruses. J Virol 75: 10118–10131.
[3]	Reed DS, Lind CM, Sullivan LJ, Pratt WD, Parker MD (2004) Aerosol Infection of Cynomolgus Macaques with Enzootic Strains of Venezuelan Equine Encephalitis Viruses. J Infect Dis 189(6): 1013–1017.
[4]	Smith JF, Davis K, Hart MK, Ludwig GV, McClain DJ, et al. (1997) Viral encephali-tides. Textbook of Military Medicine; Medical Aspects of Chemical and Biological Warfare. Washington DC: Office of surgeon general. pp. 561–589.
[5]	Powers AM, Oberste MS, Brault AC, Rico-Hesse R, Schmura SM, et al. (1997) Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus. J Virol 71: 6697–6705.
[6]	Weaver SC, Salas R, Rico-Hesse R, Ludwig GV, Oberste MS, et al. (1996) RB: Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group Lancet 348: 436–440.
[7]	Sudia WD, Newhouse VF, Beadle ID, Miller DL, Johnston JG Jr, et al. (1975) Epidemic Venezuelan equine encephalitis in North America in 1971: vector studies. Am J Epidemiol 101: 17–35.
[8]	Johnson KM, Martin DH (1974) Venezuelan equine encephalitis. Adv Vet Sci Comp Med 18: 79–116.
[9]	Roehrig JT, Bolin RA (1997) Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype 1 Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay. J Clin Microbiol 35(7): 1887–90.
[10]	Greiser-Wilke IM, Moenning V, Kaaden OR, Figueiredo LT (1989) Most alphaviruses share a conserved epitopic region on their nucleocapsid protein. J Gen Virol 3: 743–748.
[11]	Greiser-Wilke IM, Moennig M, Kaaden OR, Shope RE (1991) Detection of Alphaviruses in a genus-specific antigen capture enzyme immunoassay using monoclonal antibodies. J Clin Microbiol 29: 131–137.
[12]	Kirsch MI, Hülseweh B, Nacke C, Rülker T, Schirrmann T, et al. (2008) Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol 8: 66.
[13]	Duggan JM, Coates DM, Ulaeto DO (2001) Isolation of single-chain antibody fragments against Venezualan Equine Encephalomyelitis virus from two different immune sources. Viral Immunol 14: 263–273.
[14]	Hu WG, Alvi AZ, Fulton RE, Suresh MR, Nagata LP (2002) Genetic engineering of streptavidin-binding peptide tagged single-chain variable fragment antibody to Venezuelan equine encephalitis virus. Hybrid Hybridomics 21(6): 415–420.
[15]	Hu WG, Thompson HG, Alvi AZ, Nagata LP, Suresh MR, et al. (2004) Development of immunofiltration assay by light addressable potentiometric sensor with genetically biotinylated recombinant antibody for rapid identification of Venezuelan equine encephalitis virus. J Immunol Methods 289(1–2): 27–35.
[16]	Marschall HJ, Setzke M, Vo？ L (1995) Ringversuche Arbovirus-Testsystem, Teil 1, Testoptimierung. Defence R&D Germany, Technical Report EC1055.
[17]	Marschall HJ, Setzke M, Vo？ L (1996) Arbovirus-Testsystem, Arbeiten zur Einführung eines gruppenspezifischen ELISA zum Nachweis der Alphaviren, Teil 1, Testoptimierung. Defence R&D Germany, Technical Report EC1178–EC1179.
[18]	Huelseweh B, Ehricht R, Marschall HJ (2006) A simple and rapid protein array based method for the simultaneous detection of biowarfare agents. Proteomics 6(10): 2972–2981.
[19]	Ehricht R, Adelhelm K, Monecke S, Huelseweh B (2009) Application of Protein ArrayTubes to Bacteria, Toxin and Biological Warfare Agent Detection. In: Microchip Methods in Diagnostics. Bilitewski, U (Ed), Springer, New York, USA 509: 85–105.
[20]	Dai X, Fulton RE, Hilsen R, Hu WG, Ranches J (2008) Rapid and sensitive detection of Venezuelan equine encephalitis virus by electrochemiluminescence immunoassay. Defence R&D Canada, Technical Report, DRDC Suffield TR2008–050.
[21]	Berge TO, Gleiser CA, Gochenour WS , Miesse ML, et al. (1961) Studies on the virus of Venezuelan equine encephalomyelitis. II. Modification by specific immune serum of response of central nervous system of mice. J Immunol 87: 509–517.
[22]	Pratt WD, Davis NL, Johnston RE, Smith JF (2003) Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21: 3854–3862.
[23]	Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, et al. (2010) Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus. Vaccine 28: 3143–3151.
[24]	McKinney RW, Berge TO, Sawyer WD, Tigertt WD, Crozier D (1963) Use of an attenuated strain of Venezuelan equine encephalomyelitis virus for immunization in man. Am J Trop Med 12(4): 597–603.
[25]	McKinney RW (1972) Inactivated and live VEE vaccines - A review. pp. 369–389. PAHO Scientific Publication: Proc of the workshop symposium on Venezuelan Encephalitis.
[26]	Pittmann PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, et al. (1996) Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14(4): 337–43.
[27]	Phillpotts RJ, Wright AJ (1999) TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus. Vaccine 17(7–8): 982–988.
[28]	Alevizatos AC, McKinney RW, Feigin RD (1967) Live attenuated Venezuelan equine encephalomyelitis virus vaccine. I.Clinical effects in man. Am J Trop Med Hyg 16: 762–768.
[29]	Casamassima AC, Hess LW, Marty A (1987) TC-83 Venezuelan equine encephalitis vaccine exposure during pregnancy. Teratology 36: 287–289.
[30]	Eddy GA, Martin DH, Reeves WC, Johnson KM (1972) Field studies of an attenuated Venezuelan equine encephalomyelitis vaccine strain TC-83. Infect Immun 5(2): 160–163.
[31]	Rayfield EJ, Gorelkin L, Curnow RT, Jahrling PB (1976) Virus-induced pancreatic disease by Venezuelan encephalitis virus. Alterations in glucose tolerance and insulin release. Diabetes 25: 623–631.
[32]	Bennett AM, Elvin SJ, Wright AJ, Jones SM, Phillpotts RJ (2001) An immunological profile of BALB/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 19: 337–347.
[33]	USDA Animal Welfare Act (AWA), 7 U.S.C. 2131 et seq., as amended and Health Research Extension Act of 1985 (“Animals in Research”), Public Law 99–158.
[34]	Guide for the Care and Use of Laboratory Animals, National Research Council (1996)
[35]	Sagripanti JL, Hülseweh B, Grote G, Vo？ L, B？hling K, et al. (2011) Microbial Inactivation for Safe and Rapid Diagnostics of Biological Threat Agents. Applied Environmental Micobiology 77(20): 7289–7295.
[36]	Phillpotts RJ (2006) Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Research 120: 107–112.
[37]	O'Brien LM, Underwood-Fowler CD, Goodchild SA, Phelps AL, Phillpotts RJ (2009) Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains. Virol J 6: 206.
[38]	Spearman C (1908) The method of right and wrong cases (constat stimuli) without Gauss formulae. Brit J Psychol 2: 227.
[39]	Kaerber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 162: 480.
[40]	Hamilton MA, Russo RC, Thurston RV (1977) “Trimmed Spearman-Karber Method for Estimating Median Lethal Concentrations in Toxicity Bioassays,” Environ Sci Technol 11(7): 714–719.
[41]	Pelat T, Hust M, Thullier P (2009) Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Reviews in Medicinal Chemistry 14: 1633–1638.
[42]	Pelat T, Hust M, Hale M, Lefranc MP, Dübel S, et al. (2009) Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 9: 60.
[43]	Pelat T, Hust M, Laffly E, Condemine F, Bottex C, et al. (2007) High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 51: 2758–2764.
[44]	Hust M, Toleikis L, Dübel S (2007) Antibody phage display. In: Weinheim DübelS, editor. Handbook of therapeutic antibodies. Willey-VCH. pp. 45–68. Edited by.
[45]	Hust M, Meyer T, Voedisch B, Rülker T, Thie H, et al. (2011) A human scFv antibody generation pipeline for proteome research. Journal of Biotechnology 152: 159–170.
[46]	Sambrook J, Fritsch , EF , Maniatis T (1989) Molecular Cloning: A Laboratory Manual, vol. I. 2nd edition. Cold Spring Harbor: Laboratory Press.
[47]	Rondot S, Koch J, Breitling F, Dübel S (2001) A helper phage to improve single-chain antibody presentation in phage display. Nat Biotech 19: 75–78.
[48]	Soltes G, Hust M, Ng KKY, Bansal A, Field J, et al. (2007) On the influence of vector design on antibody phage display. Journal Biotechnology 127: 626–637.
[49]	Schirrman T, Hust M (2010) Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol. Biol 651: 177–209.
[50]	Kirsch M, Zaman M, Meier D, Dübel S, Hust M (2005) Parameters affecting the display of antibodies on phage. Journal of Immunological Methods 301: 173–185.
[51]	Henchal EA, Gentry MK, McCown JM, Brandt WE (1982) Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immuno-fluorescence. Am J Trop Med Hyg 31: 830–836.
[52]	Mollova S, Retter I, Hust M, Dübel S, Müller W (2010) Analysis of single chain antibody sequences using the VBASE2 Fab Analysis Tool. In: Kontermann R, Dübel S, editors. Antibody engineering Vol 2. Springer-Verlag. pp. 3–10.
[53]	Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
[54]	Jensen H (1981) Detection of antibodies against hog cholera virus and bovine viral diarrhea virus in porcine serum. A comparative examination using CF, PLA and NLPA assays. Acta Vet Scand 22: 85–98.
[55]	Roehrig JT, Mathews JH (1985) The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. Virology 142(2): 347–56.
[56]	May KR (1973) The Collison nebulizer: description, performance and application. Journal of Aerosol Science 4: 235–243.
[57]	Henderson DW (1952) An apparatus for the study of airborne infection. Journal of Hygiene 50: 53–68.
[58]	Wright AJ, Phillpotts RJ (1998) Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice. Archives of Virology 143: 1155–1162.
[59]	Thullier P, Huish O, Pelat T, Martin AC (2010) The humanness of macaque antibody sequences. J Mol Biol 396(5): 1439–50.
[60]	Murphy KM, Travers P, Walport M (2009) Janeway's Immunology. 7th ed., Garland Science, Taylor & Francis Group.
[61]	Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT (2006) A humanised murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol 87: 2467–2476.
[62]	Hunt AR, Richard A, Bowen B, Fredericksonc S, Maruyamad T, et al. (2011) Treatment of mice with human monoclonal antibody 24 h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology 414: 146–152.
[63]	Roehrig JT, Day JW, Kinney RM (1982) Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 118(2): 269–78.
[64]	Steele KE, Twenhafel NA (2010) Pathology of animal models of alphavirus encephalitis. Vet Pathol 47(5): 790–805.
[65]	Charles PC, Trgovcich J, Davis NL, Johnston RE (2001) Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-induced disease in the mouse. Virology 284(2): 190–202.
[66]	Charles PC, Walters E, Margolis F, Johnston RE (1995) Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 208(2): 662–671.
[67]	Luers AJ, Adams SD, Smalley JV, Campanella JJ (2005) A phylogenomic study of the genus Alphavirus employing whole genome comparison. Comp Funct Genomics 6(4): 217–227.
[68]	Goodchild SA, O'Brien LM, Steven J, Muller MR, Lanning OJ, et al. (2011) A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res 90(1): 1–8.
[69]	Hu WG, Phelps AL, Jager S, Chau D, Hu CC, et al. (2010) A recombinant humanised monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus. Vaccine 28: 5558–5564.
[70]	De Mucha-Macias J, Sanchez-Spindola I (1965) Two human cases of laboratory infection with Mucambo virus. Am J Trop Med Hyg 14(3): 475–478.
[71]	Dietz WH, Peralta PH, Johnson KM (1979) Ten clinical cases of human infection with Venezuelan Equine Encephalomyelitis Virus, Dubtype ID. Am J Trop Med Hyg 28(2): 329–332.
[72]	McCurdy K, Joyce J, Hamilton S, Nevins C, Sosna W, et al. (2011) Differential accumulation of genetic and phenotypic changes in Venezuelan equine encephalitis virus and Japanese encephalitis virus following passage in vitro and in vivo. Virology 415(1): 20–29.
[73]	Wust CJ, Nicholas JA, Fredin D, Dodd DC, Brideau RJ, et al. (1989) Monoclonal antibodies that cross-react with the E1 glycoprotein of different alphavirus serogroups: characterization including passive protection in vivo. Virus Res 13(2): 101–112.
[74]	Phillpotts RJ, Wright AJ (1999) TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus. Vaccine 17(7–8): 982–988.
[75]	Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD (2010) The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis 4(7): 739.
[76]	Mathews JH, Roehrig JT, Trent DW (1985) Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. Journal of Virology 55: 594–600.
[77]	Wust CJ, Crombie R, Brown A (1987) Passive protection across subgroups of alphaviruses by hyperimmune non-cross-neutralizing anti-Sindbis serum. Proc Soc Exp Biol Med 184(1): 56–63.
[78]	Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA (1982) Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297: 70–72.
[79]	Phillpotts RJ, Jones LD, Howard SC (2002) Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 20(11–12): 1497–504.
[80]	Parker MD, Buckley MJ, Melanson VR, Glass PJ, Norwood D, et al. (2010) Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection. J Virol 84: 12683–12690.
[81]	Pelat T, Thullier P (2009) Non-human primate immune libraries combined with germline humanization: an (almost) new and powerful approach for the isolation of therapeutic antibodies. MAbs 1(4): 377–81.
[82]	Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc MP, et al. (2008) Germline humanization of a non-human Primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384: 1400–1407.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133